Glaxosmithkline LLC

Duke M Fitch

Antony N Shaw

Kenneth Wiggall

Kevin J Duffy

Jian Jin

Ronggang Liu

Beth Adams Norton

Mariela Colón

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Prolyl hydroxylase inhibitors

The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) 

Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors

Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6 -dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.

5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one

Growing community of inventors

Collegeville, PA, United States of America

Duke M Fitch